2014
DOI: 10.4067/s0034-98872014000600004
|View full text |Cite
|
Sign up to set email alerts
|

Leucemia linfoblástica aguda estirpe B Philadelphia negativa en adolescentes y adultos jóvenes: Resultados del Protocolo Terapéutico LLA 15-30, Programa Nacional de Cáncer del Adulto (PANDA), Ministerio de Salud, Chile

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
2
0
2

Year Published

2016
2016
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(4 citation statements)
references
References 20 publications
0
2
0
2
Order By: Relevance
“…The main chemotherapy regimens consisted of HyperCVAD and the Chilean young-adult protocol known as "15–30" [4] . In the case of BCR-ABL fusion gene detection, a tyrosine kinase inhibitor was added, and Rituximab was added for CD20-positive marker.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…The main chemotherapy regimens consisted of HyperCVAD and the Chilean young-adult protocol known as "15–30" [4] . In the case of BCR-ABL fusion gene detection, a tyrosine kinase inhibitor was added, and Rituximab was added for CD20-positive marker.…”
Section: Methodsmentioning
confidence: 99%
“…In 2014, results from the national protocol known as “15–30” were reported. This was an adaptation of the Children's Oncology Group AALL0232 protocol [3] , which included 68 patients between the ages of 15 and 32, and reported a 3-year overall survival of 61% [4] . T-lineage patients were not included.…”
Section: Introductionmentioning
confidence: 99%
“…En el día decimosegundo tenía paraplejia fláccida, ROT abolidos, sin nivel sensitivo. Un hemograma con recaída leucémica en el día decimo-Tabla 1. protocolo nacional pANDA inducción Quimioterapia intratecal triple (Metotrexato 15 mg, Citarabina 50 mg, Betametasona 4 mg) día 8 y 29 Dexametasona 10 mg/m 2 /día, IV, días 1 al 14 Vincristina 1,5 mg/m 2 /día, IV, (dosis máx 2 mg), días 1,8,15,22 Daunorrubicina 25 mg/m 2 /día, IV, días 1, 8, 15, 22 L-asparaginasa **6.000 U/m 2 ,IM,días 15,17,19,22,24,26 y 29 nono obligó a continuar con cuidados paliativos en su domicilio. El compromiso neurológico no progresó, falleciendo de la LLA.…”
Section: Casounclassified
“…Salvador 364, Providencia, Santiago, Chile. lcartier@med.uchile.cl L a triple asociación de Metrotrexato, Citarabina y Betametazona es un esquema habitual en la quimioterapia intratecal (QI), usada de manera profiláctica, o en el tratamiento de Leucemias Linfoblásticas agudas (LLA) 1 . Esporádicamente, desde la implementación de la QI, se han comunicado casos de mielopatías tóxicas asociadas a este tipo de tratamiento 2 .…”
unclassified